Catherine Owen Adams

Chief executive: Acadia Pharmaceuticals Inc. (23 Sep 2024 to present)

10commitments announced

5with a clear outcome

5met on time

–rate shown after 15 outcomes

Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Acadia Pharmaceuticals Inc. filing.

Commitments announced under Catherine Owen Adams

Acadia Pharmaceuticals Inc.announced 6 May 2026	Report topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis	Open31 Oct 2026
Acadia Pharmaceuticals Inc.announced 6 May 2026	Report topline results from the trofinetide clinical trial in Japan	Open30 Nov 2026
Acadia Pharmaceuticals Inc.announced 25 Feb 2026	Launch the DAYBUE STIX powder formulation	Met30 Jun 2026
Acadia Pharmaceuticals Inc.announced 6 Aug 2025	Initiate seven Phase 2 or Phase 3 studies	Open31 Dec 2026
Acadia Pharmaceuticals Inc.announced 6 Aug 2025	Provide five clinical trial readouts	Open31 Dec 2027
Acadia Pharmaceuticals Inc.announced 26 Feb 2025	Initiate a Phase 2 study of ACP-204 for Lewy Body Dementia Psychosis	Met30 Sep 2025
Acadia Pharmaceuticals Inc.announced 26 Feb 2025	Enroll the last patient in the COMPASS PWS Phase 3 study	Met31 Dec 2025
Acadia Pharmaceuticals Inc.announced 26 Feb 2025	Enroll the last patient in the RADIANT Phase 2 study	Met31 Mar 2026
Acadia Pharmaceuticals Inc.announced 26 Feb 2025	Announce topline results for the COMPASS PWS Phase 3 study	Met30 Jun 2026
Acadia Pharmaceuticals Inc.announced 26 Feb 2025	Initiate a Phase 2 study in essential tremor	Open31 Dec 2026

Is this record wrong, or are you Catherine Owen Adams? Add a statement or ask for a correction.

Commitments announced under Catherine Owen Adams

The Deadline Report